@AMCTheatres i want to sign for “a list classic” that’s advertised on your website for $14.99 a month and 1 movie per week but every time I click the link it tries to enroll me in a list premium for $23.99 a month. Can you please advise on how to sign up for the classic plan?
I finally read the Project 2025's proposals for education. It's easy enough to say "abolish the department of education." I mean, who outside of Washington actually cares about how the federal government organizes its education programs? But what you might care about is that
@tmprowell Also worth considering…individual coffee pod machines with coffee inside plastic brewing pods were introduced into the household market in 2004. 20 years ago…
Wading into this water bottle debate as a cancer doctor. There has been a striking increase in #coloncancer in people under age 50. When you see an abrupt change like this by generation, it always raises concern for an environmental cause. #MedTwitter https://t.co/whDtW0qwwZ
@marklewismd Having empathy for you patients while practicing in oncology is a strength. Trust me, patients know which oncologists have it and which ones don’t. It makes a difference…YOU make a difference.
1/Please share this thread on behalf of my physician colleague, Eunice Stallman, who is facing the nightmare of her 9mo daughter, Zoey, being diagnosed with brain cancer several weeks ago. @BlueCrossIdaho has added to their anguish by obstructing access to vital treatment.
One of the most impactful projects I have been fortunate to be part of with many incredible collaborators, @felixfengmd , @NRGonc , @arteraAI all coming together to create the 1st validated predictive biomarker for ADT use in PCa.
Big win for patients!
@uhradonc @caseccc#PCSM
#ASCO23@asco PEACE-1 trial by Dr. Bossi👉Significant delay in disease progression and delay of serious GU obstructive events by radiation therapy in mCSPC (no OS benefit): results confirm the role of radiation in low volume denovo mCSPC @OncoAlert@urotoday@PCFnews
#EAU21 is over, now it's time for another @EurUrolOncol#SoMe Award. This month's winner is...
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy & Improves Clinical Outcomes in Oligoprogressive CRPC
https://t.co/KIHmiSjGQM
Congrats to @matthewdeek@KekoaMDPhD
🚀 #JCO#RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer
🎯 Largest benefit for patients harboring a high-risk mutation #PCSM@matthewdeek@piet_ost https://t.co/OO8kcTVvFT
We join the oncology community in mourning the loss of A. William Blackstock Jr., MD, FASCO, who served on our Board of Directors from 2018-2022.
Read more about Dr. Blackstock’s life, work, and legacy: https://t.co/QelLOXkflf
Breaking news👉@US_FDA approves Talazoparib + Enzalutamide for mCRPC #prostatecancer with HRR mutations. Weblink👉 https://t.co/adGntAZAnb Efficacy data, HRR mutations👇@PCFnews@OncoAlert@urotoday@huntsmancancer Gratifying to see the success of this trial we started 6 yrs ago